Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02251912 · ClinicalTrials.gov registry record · Phase 2
Oxytocin Treatment of Alcohol Dependence
A Phase 2 study of Alcohol Dependence, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT02251912 is a Phase 2 study of Alcohol Dependence that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 22 participants, below the 313-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02251912, a Phase 2 study of Alcohol Dependence, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: Test whether oxytocin treatment decreases drinking in people who have been consuming alcohol heavily for long periods and are physically and psychologically dependent on alcohol. Participants: 50 adults with alcohol dependence Procedures (methods): Oxytocin or placebo will be administered three times a day for the first 2 days followed by twice daily intranasal doses for the rest of the 12 weeks. Before, during and at the end of the trial, each subject will undergo evaluations including breathalyzer readings, rating withdrawal symptoms, interviews about amount of alcohol consumed since last clinic visit, subject self-ratings of anxiety, alcohol craving and, at some visits, laboratory measures (blood and urine) to monitor safety and alcohol/drug use. Following the active phase of the trial, subjects will be followed up at 4 weeks and 12 weeks to evaluate for post-medication safety and efficacy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Intranasal Oxytocin
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02251912
The ClinicalTrials.gov registry entry for NCT02251912 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 313-participant average among 43 other Alcohol Dependence trials with a reported enrollment target (93% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Dependence appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02251912 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02251912 about?
NCT02251912 is a clinical study titled "Oxytocin Treatment of Alcohol Dependence". Purpose: Test whether oxytocin treatment decreases drinking in people who have been consuming alcohol heavily for long periods and are physically and psychologically dependent on alcohol. Participants: 50 adults with alcohol dependence Procedures (methods): Oxytocin or placebo will be administered...
What is the current status of trial NCT02251912?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-07. Estimated completion is 2016-09.
What conditions does trial NCT02251912 study?
This clinical trial studies the following conditions: Alcohol Dependence.
What interventions are being tested in trial NCT02251912?
The interventions under investigation include: Placebo (DRUG), Intranasal Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02251912?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02251912 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
The MEADOW PROJECT (Mending the Effects of Alcohol and Depression on Women) and The Bridge Program (Connecting Recovery Treatment and Behavioral Health)
COMPLETED · Phase 2
-
Neuromodulation of Trauma Memories in PTSD & Alcohol Dependence
COMPLETED · Phase 2
-
A Therapeutic Workplace for Alcohol Dependence
COMPLETED · Phase 2
-
Modification of Cognitive Processing Therapy (CPT-C) for PTSD and Alcohol Dependence
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.